Stockscreener 앱 받기
83.58
4.25%
-3.71
시장 영업 전:
84.37
0.79
+0.95%
Dexcom Inc 주식(DXCM)의 최신 뉴스
Dexcom EVP Brown sells $41k in shares - Investing.com
Diabetics at Risk: FDA Issues Highest-Level Recall on 2M Dexcom Devices Over 'Deadly Fault' - inkl
Global Artificial Pancreas Devices Market is Gearing Up for Outstanding Expansion at a CAGR of ~16% by 2032 | DelveInsight - GlobeNewswire Inc.
Dexcom Ireland announce golfer Liam Nolan as a brand ambassador - Galway Advertiser
Dexcom recalls more than 2 million CGM receivers for lack of audible alarm - MedTech Dive
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025 - Dexcom
Breakthrough Study Reveals Doctors Choose CGM Over Medications as Future of Type 2 Diabetes Treatment - Stock Titan
Q1 Rundown: DexCom (NASDAQ:DXCM) Vs Other Patient Monitoring Stocks - FinancialContent
Dexcom Faces TM Suit Over 'Stelo' Glucose Monitor Product - Law360
Goldman Sachs Initiates Coverage of DexCom (DXCM) With Buy Rating - MSN
DexCom’s SWOT analysis: CGM leader’s stock poised for growth amid challenges - Investing.com
DexCom's SWOT analysis: CGM leader's stock poised for growth amid challenges - Investing.com
Expert Outlook: DexCom Through The Eyes Of 8 Analysts - Nasdaq
DexCom Stock: Is DXCM Underperforming the Health Care Sector? - MSN
DexCom (DXCM) Receives 'Buy' Rating from Truist Securities with $102 Price Target | DXCM Stock News - GuruFocus
DexCom (DXCM) Gains Analysts' Favor Despite Past Challenges - GuruFocus
DexCom Stock: Is DXCM Underperforming The Health Care Sector? - Barchart.com
DexCom (DXCM) Receives Buy Rating Amid Promising Market Prospects | DXCM Stock News - GuruFocus
Truist Initiates DexCom at Buy With $102 Price Target - MarketScreener
DexCom Insiders Sell US$11m Of Stock, Possibly Signalling Caution - simplywall.st
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - Business Wire
Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7 - MassDevice
Insulet Corporation's Omnipod 5 App for Iphone with Dexcom G7 Integration Now Available to All U.S. Users - marketscreener.com
Insulet Releases Omnipod 5 App for iPhone with Dexcom G7 CGM in U.S. - Medical Product Outsourcing
Diabetes partnerships abound ahead of ADA - BioWorld MedTech
Insulet's Omnipod® 5 App For iPhone With Dexcom G7 Integration Now Available To All US Users - MarketScreener
Insulet (PODD) Omnipod 5 App Now Compatible with Dexcom G7 on iPhone | PODD Stock News - GuruFocus
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users | PODD Stock News - GuruFocus
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users - Business Wire
DexCom, Inc. (DXCM) Stock Analysis: Analyst Consensus Points to 13.59% Potential Upside - DirectorsTalk Interviews
DexCom (NASDAQ:DXCM) Stock Rating Upgraded by Wall Street Zen - Defense World
DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire
BGM and CGM Market is Set to Experience a Revolutionary Growth | Abbott Laboratories , Dexcom, Medtronic PLC - openPR.com
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Should You Be Excited About DexCom, Inc.'s (NASDAQ:DXCM) 24% Return On Equity? - simplywall.st
Goldman Sachs Initiates Coverage of DexCom (XTRA:DC4) with Buy Recommendation - Nasdaq
Goldman Sachs Initiates Coverage of DexCom (BIT:1DXCM) with Buy Recommendation - Nasdaq
DexCom (NASDAQ:DXCM) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Goldman Sachs Initiates Coverage of DexCom (DXCM) with Buy Recommendation - Nasdaq
Forecasting The Future: 7 Analyst Projections For DexCom - Benzinga
DexCom, Inc. (NASDAQ:DXCM) Q2 2024 Earnings Call Transcript - MSN
Jefferies Adjusts Price Target on DexCom to $110 From $105, Maintains Buy Rating - marketscreener.com
Goldman Sachs Initiates DexCom at Buy With $104 Price Target - marketscreener.com
DexCom (DXCM) Receives Positive Coverage with Growth Potential | - GuruFocus
DexCom (DXCM) Receives Positive Coverage with Growth Potential | DXCM Stock News - GuruFocus
Dexcom’s EVP Sadie Stern sells $526,318 in shares - Investing.com
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - The Globe and Mail
DexCom, Inc. (DXCM) Stock Analysis: 15.97% Potential Upside Amid Robust Analyst Support - DirectorsTalk Interviews
DexCom’s SWOT analysis: CGM leader faces supply challenges amid growth - Investing.com
DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move? - Smartkarma
An Intrinsic Calculation For DexCom, Inc. (NASDAQ:DXCM) Suggests It's 27% Undervalued - Yahoo Finance
Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.
DexCom (DXCM) Maintains Buy Rating as Price Target Raised to USD 102 | DXCM Stock News - GuruFocus
Citi Increases Price Target for DexCom (DXCM) to $102 | DXCM Sto - GuruFocus
Citi Increases Price Target for DexCom (DXCM) to $102 | DXCM Stock News - GuruFocus
Dexcom (DXCM) Gets a Buy from Wells Fargo - The Globe and Mail
DexCom adds Renée Galá to Board of Directors By Investing.com - Investing.com Nigeria
3 Big Reasons to Love DexCom (DXCM) - Yahoo Finance
2.54%
1.32%
자본화:
|
볼륨(24시간):